1 withdrawn. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Withdrawn 1 |
Follow NMIBC: new trials by email Literature Review of NMIBC trials Research Report on NMIBC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) - NMIBC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-15 | 2026-05-19 |
Non-Muscle Invasive Bladder Neoplasms (1)
Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Urinary Bladder Diseases (1) · Urinary Bladder Neoplasms (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)